Dr Evidence (DRE), an AI-Enabled SaaS Healthcare Insights Company, Taps Industry Experts Joseph A. Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its Newly Formed Medical Strategy Advisory Board
DRE is pleased to welcome Joe Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its newly formed Medical Strategy Advisory Board (MSAB). These enhancements to the Company reflect the expanded need for keen guidance in this unprecedented time of convergence between expert AI-enabled technology in healthcare and the exponential growth of clinical information. DRE is dedicated to applying sophisticated data science with advanced AI to generate quicker, deeper, more nuanced regulatory-grade scientific and clinical insights for the betterment of patient outcomes.
Boystak is an experienced healthcare venture capitalist and senior healthcare investment banker having been Founding Managing Partner at Health2047 Capital Partners and Founding Managing Director, Global Life Sciences at Jefferies. He is CEO of Brightwaters Capital and is a serial co-founder/investor in biomedical, med tech, health information technology, and artificial intelligence companies with spinouts from UCLA, Johns Hopkins, Harvard/Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, among others. Boystak is also named co-inventor on 5 issued US/EU patents for first-in-class medical technology developed by Bruin Biometrics LLC, a company he co-founded and was its initial Chairman. He has served on more than a dozen corporate and non-profit boards and currently serves on the Johns Hopkins Bloomberg School of Public Health and Southern California Biomedical Council (SoCalBio) Boards.
“I am honored to join the DRE Board as its Chairman. DRE’s industry leading SaaS platform is facilitating AI-driven drug discovery as pharma and life sciences companies rapidly adopt this technology,” stated Boystak. “Our SaaS platform enables, among others, researchers and drug developers to optimize drug design, improve clinical trial effectiveness, rapidly explore repurposing of compounds, refine FDA label strategies and improve product life cycle management - thus creating substantial ROI for our clients.”
Ameet Nathwani, MD, is Chairman of the newly created MSAB, which will initially consist of five members that represent industry, specialty medical societies, regulatory, data science and patient advocacy. Dr. Nathwani’s most recent position as Executive Vice President, Chief Medical Officer and Chief Digital Officer at Sanofi provides a great framework for the MSAB to inform DRE on strategy, regulatory requirements, research and development, technology and trends in clinical care. The MSAB will also advise on healthcare ecosystem partners for DRE to collaborate with to accelerate treatments and cures.
“It is a privilege to be appointed as the Chairman of the DRE MSAB. At a time when the volume and complexity of scientific data is increasing exponentially, the AI-driven DRE platform provides a state-of-the-art tool which gives healthcare organizations the ability to deconvolute critical scientific data. This agile approach to make rigorous and rapid decisions of real-world data is critical to innovate in this dynamic century of biology,” said Ameet Nathwani, MD. “The MSAB will advise DRE on enhancing the many scientific and healthcare applications of the platform in order to best support a diverse spectrum of partners that will ultimately benefit physicians and patients.”
“With our expanded SaaS platform now including the launch of DOC Analytics™ we are that much closer to achieving our mission of democratizing sophisticated analysis of clinical studies and real-world data for researchers,” added Bob Battista, MBA, FRCPH, FRCP Edin. “We have been fortunate to be backed by a committed group of investors and Board members that Joe will now lead as we chart our next stage of growth. We are similarly privileged to have Dr. Nathwani lead our newly established MSAB. Ameet’s deep sector knowledge and passion for DRE’s SaaS platform provide an incredible basis for guiding our healthcare strategy.”
Joe Boystak and Ameet Nathwani, MD, join a distinguished group of Corporate Board members at DRE that include: Marc Rapaport, immediate past Chairman of DRE, immediate past Chairman of the Board of Cedars-Sinai Medical Center (Los Angeles), private equity investor, and former Executive Vice President and Co-Head of Capital Markets at Drexel Burnham Lambert and Jefferies; Vivek Garipalli, CEO and Co-Founder Clover Health, Co-Founder CarePoint Health, and an active investor in early stage healthcare companies, including founding investor in Flatiron; Ted Meisel, serial healthcare and technology entrepreneur, Executive Founder of AVIA, Executive Chairman of WiserCare, Senior Advisor NextEquity Partners, past Senior Advisor to the Center for Medicare and Medicaid Services (CMS), past President Yahoo Search and past CEO of Overture (acquired by Yahoo); Ananth Bhogaraju, Founder and Managing Director Seven Hills Healthcare Advisors and past Vice Chairman Americas Healthcare Investment Banking Deutsche Bank; Larry Burstein, a healthcare focused Family Office career fund manager; Bob Battista, Co-Founder and CEO DRE, serial healthcare and technology entrepreneur, past Executive Vice President at TheraCom, the first ever specialty pharmacy; and Todd Feinman, MD, Co-Founder and Chief Medical Officer DRE, Hospitalist at Cedars-Sinai Medical Center (Los Angeles) and Director of a large Independent Physician Association.
ABOUT DRE
DRE is a market leading company in the AI-enabled health technology marketplace that deploys state-of-the-art solutions to identify, synthesize, and analyze complex clinical data into actionable insights. DRE provides instant, continuous search and data analysis across critical functions of Pharmaceutical, Biotech, Life Sciences and Medical Technology companies to optimize their clinical programs. Its technology platform provides DRE's customers with a Software-as-a-Service ("SaaS") Insights Engine which empower them to make better decisions from lab to patient.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005298/en/
Contact information
Chris Yu
pr@doctorevidence.com
+1 (310) 595-1265
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Tourism Surging Ahead of Economic Growth, With Visits to Hit 30 Billion by 20344.7.2025 02:00:00 EEST | Press release
The World Economic Forum has today published a new report forecasting that the travel and tourism industry is projected to serve 30 billion tourist trips by 2034. Travel and Tourism at a Turning Point: Principles for Transformative Growth, produced in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, reveals a projected $16 trillion contribution to global GDP by the same year—representing more than 11% of the total world economy, according to World Travel & Tourism Council estimates. The report also found that the sector is expanding 1.5 times faster than the global economy, generating significant commercial opportunities as long as the mounting challenges of climate change, labour shortages and infrastructure gaps are addressed. Inbound and outbound trips increasing fast Asia is on track to become the world’s fastest-growing tourism economy, with the direct travel and tourism GDP contribution expected to exceed 7% across the region by 2034. Notably, India and China
The 2025-2026 World Branding Awards Animalis Edition Honouring Leading Pet and Animal Brands Globally3.7.2025 22:00:00 EEST | Press release
The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from all around the world. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. “The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,” said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominate
Venture Global Announces 20-Year Sales and Purchase Agreement with PETRONAS3.7.2025 15:59:00 EEST | Press release
Today, Venture Global, Inc. (NYSE: VG) announced the execution of a new 20-year Sales and Purchase Agreement (SPA) with PETRONAS LNG Ltd. (PLL), a subsidiary of the Malaysian state-owned oil and gas company, PETRONAS. Under the terms of the SPA, PETRONAS will purchase 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global’s third facility, CP2 LNG, for 20 years. This builds upon Venture Global’s existing agreement with PETRONAS for 1 MTPA of LNG supply from Plaquemines LNG. PETRONAS, a world-class partner in the LNG industry, joins other CP2 LNG customers in Europe, Asia and the rest of the world in a strategically important project to global energy supply and security. To date, approximately 10.75 MTPA of the 14.4 MTPA nameplate capacity for CP2 Phase One has been sold. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets ac
Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year3.7.2025 15:05:00 EEST | Press release
In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703950144/en/ Novotech Wins Global CRO Award Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. “Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for
Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model3.7.2025 13:02:00 EEST | Press release
The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure. As there is currently no causal treatment for tinnitus, there is a high medical need. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702168211/en/ In 10-20% of tinnitus cases, the noise in the ear is so severe that it significantly impairs the quality of life of those affected. (Source: AI-generated) In the current study, AC102 was administered to the middle ear of one experimental group after acoustic trauma, while a second group received a placebo. Although both groups initially showed signs of tinnitus, th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom